Evidence map›Paper›PMID 28107680›Full record

Trial reportDrug and alcohol dependence2017

A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release.

Michael S Gordon, Timothy W Kinlock, Robert P Schwartz, Kevin E O'Grady, Terrence T Fitzgerald, Frank J Vocci

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Drug and alcohol dependence, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 8 pooled it
6.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 8 syntheses or guidelines pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Routes of non-traditional entry into buprenorphine treatment programs.Substance abuse treatment, prevention, and policy · 2020
    Pooled it
  5. Pooled it
  6. Interventions for female drug-using offenders.The Cochrane database of systematic reviews · 2019
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Michael S GordonFriends Research Institute, Inc., 1040 Park Avenue, Suite 103, Baltimore, MD 21201, United States. Electronic address: mgordon@friendsresearch.org.
Timothy W KinlockUniversity of Baltimore, School of Criminal Justice, 10 W. Preston Street, Baltimore, MD 21201, United States.
Robert P SchwartzFriends Research Institute, Inc., 1040 Park Avenue, Suite 103, Baltimore, MD 21201, United States; University of Maryland School of Medicine, Department of Psychiatry, 701 West Pratt Street, Baltimore, MD 21201, United States.
Kevin E O'GradyDepartment of Psychology, University of Maryland, 4094 Campus Drive, College Park, MD 20742, United States.
Terrence T FitzgeraldGlenwood Life Counseling Center, 516 Glenwood Avenue, Baltimore, MD 21212, United States.
Frank J VocciFriends Research Institute, Inc., 1040 Park Avenue, Suite 103, Baltimore, MD 21201, United States.
Friends Research Institute · USCounseling Center · USUniversity of Baltimore · USUniversity of Maryland, Baltimore · USUniversity of Maryland, College Park · US

Funding

Buprenorphine for PrisonersR01DA021579 · NIDA · FRIENDS RESEARCH INSTITUTE, INC. · PI KINLOCK, TIMOTHY W · 2007 to 2011
$2.7M
NIDA NIH HHS R01 DA021579
6 · The paper itself

Abstract

backgroundThis study examined whether starting buprenorphine treatment prior to prison and after release from prison would be associated with better drug treatment outcomes and whether males and females responded differently to the combination of in-prison treatment and post-release service setting.

methodsStudy design was a 2 (In-Prison Treatment: Condition: Buprenorphine Treatment: vs. Counseling Only)×2 [Post-Release Service Setting Condition: Opioid Treatment: Program (OTP) vs. Community Health Center (CHC)]×2 (Gender) factorial design. The trial was conducted between September 2008 and July 2012. Follow-up assessments were completed in 2014. Participants were recruited from two Baltimore pre-release prisons (one for men and one for women). Adult pre-release prisoners who were heroin-dependent during the year prior to incarceration were eligible. Post-release assessments were conducted at 1, 3, 6, and 12-month following prison release.

resultsParticipants (N=211) in the in-prison treatment condition effect had a higher mean number of days of community buprenorphine treatment compared to the condition in which participants initiated medication after release (P=0.005). However, there were no statistically significant hypothesized effects for the in-prison treatment condition in terms of: days of heroin use and crime, and opioid and cocaine positive urine screening test results (all Ps>0.14) and no statistically significant hypothesized gender effects (all Ps>0.18).

conclusionsAlthough initiating buprenorphine treatment in prison compared to after-release was associated with more days receiving buprenorphine treatment in the designated community treatment program during the 12-months post-release assessment, it was not associated with superior outcomes in terms of heroin and cocaine use and criminal behavior.

Indexed as

PrisonersAdultBuprenorphineCocaine-Related DisordersCounselingCrimeFemaleFollow-Up StudiesHeroin DependenceHumansMaleMiddle AgedNarcotic AntagonistsOpioid-Related DisordersRecurrenceSex CharacteristicsBuprenorphineNarcotic AntagonistsBuprenorphineHeroin addictionOpioid substitution therapyPrisoners

Identifiers

PMID28107680
PMCPMC5309171
OpenAlexW2575419532

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.